April 28, 2026
Last Updated: April 2026
On April 22, 2026, the Acting Attorney General signed a final order moving two narrow categories of marijuana from Schedule I to Schedule III of the Controlled Substances Act. The Federal Register published the corresponding rules on April 28. Within hours, every operator group, multi-state holding company, and cannabis-focused law firm had a press release ready. Most got the headline right and the substance wrong.
This is what the Trump administration's cannabis rescheduling actually did, and — just as importantly — what it didn't do. If you operate a state-licensed business, advise one, finance one, or audit one, the legal posture you held on April 21 is no longer the posture you hold today. The change is real. It is also smaller than the term "rescheduling" suggests, and the carve-outs matter more than the headline.
The final order reschedules two categories of cannabis to Schedule III: FDA-approved drug products containing marijuana, and marijuana subject to a qualifying state-issued license to manufacture, distribute, or dispense for medical purposes only. Recreational cannabis — even where state-legal — stays in Schedule I. Bulk plant material, unlicensed activity, and synthetically derived THC also stay in Schedule I. The order took effect April 22, 2026. State medical licensees have a 60-day window to file for DEA Schedule III registration and continue operating during review. A separate DEA hearing starting June 29, 2026 will consider whether broader rescheduling — including recreational — should follow.
That's the entire universe of what changed federally. Everything else you'll read about — 280E relief, banking implications, FDA pathways, research access — flows from those facts.
The first act was the May 2024 Notice of Proposed Rulemaking from the Biden DOJ and DEA. That NPRM proposed moving all marijuana from Schedule I to Schedule III. It triggered an administrative hearing process that stalled through 2024 and into 2025 over witness disputes, ex parte communications questions, and the procedural footing of the rule itself.
The Trump administration inherited the stalled docket in January 2025. For most of the year, the conventional wisdom was that the new administration would let the proceeding die quietly. That changed on December 18, 2025, when President Trump signed an executive order titled "Increasing Medical Marijuana and Cannabidiol Research," directing the Attorney General to take all necessary steps to expeditiously move marijuana from Schedule I to Schedule III. The order specifically framed the action around medical access and research — not adult-use legalization.
What followed is the procedural choice that explains the whole shape of the April final order. Rather than push the broader May 2024 NPRM across the finish line, the administration used a separate statutory pathway built into the Controlled Substances Act: treaty-compliance rescheduling. That pathway, set out in 21 U.S.C. § 811(d), allows the Attorney General to reschedule a controlled substance to comply with U.S. obligations under the Single Convention on Narcotic Drugs without going through the full notice-and-comment apparatus. It's narrower in what it can accomplish but faster, and it bypasses the contested administrative hearing record entirely.
The April 22 final order is that treaty-compliance move. The June 29 hearing is the resumed broader rulemaking. They are running on parallel tracks for a reason — and the reason has direct consequences for what your business can and can't claim today.
The final order, codified at 21 C.F.R. § 1308.13, places the following into Schedule III:
The order also covers marijuana extracts and naturally derived delta-9-tetrahydrocannabinol from the cannabis plant — but only to the extent those substances are incorporated into an FDA-approved product or covered by a qualifying state medical marijuana license.
The "medical purposes only" qualifier is doing real work. A state license that authorizes both medical and adult-use activity at the same facility — common in states like Michigan, Massachusetts, and Illinois where dual-licensure is the norm — does not automatically qualify. The DEA has signaled it will look at the operational reality, not just the paper of the license. Operators with co-located medical and adult-use operations are going to need to think hard about how they segregate inventory, accounting, and DEA-registered activity from the rest of the business.
The list of what didn't move matters more than the list of what did:
Recreational, adult-use cannabis remains a Schedule I controlled substance. Every state-legal adult-use dispensary in the country is, on April 28, 2026, in exactly the same federal posture it was in on April 21. Federal trafficking exposure, banking restrictions, and IRC § 280E all still apply.
Bulk plant material — flower, trim, and biomass that hasn't yet been incorporated into a finished product covered by an FDA approval or a qualifying state medical license — also stays in Schedule I. This is the counterintuitive piece of the order. A cultivator selling biomass into a chain of medical-only finished-goods manufacturing isn't obviously rescheduled until the product reaches a covered category. How the DEA traces that chain through registration is one of the dominant unanswered questions of the next 90 days.
Unlicensed activity stays in Schedule I, full stop. There is no implicit federal protection for operators outside a qualifying state-issued license, and the order doesn't create one.
Synthetically derived THC — the broader hemp-cannabinoid universe of Delta-8, semi-synthetic THCa, and converted hemp-derived intoxicants — stays in Schedule I where it sits today, layered with separate FDA and state enforcement actions that we've covered in our hemp regulation overview and the synthetic cannabinoid regulation analysis.
The two-tier federal market that this creates is the most consequential outcome of the order. State-licensed medical operators sit in one regulatory universe. State-licensed recreational operators — often the same companies, sometimes the same buildings — sit in another. The legal, tax, and compliance gap between those two universes is now larger than the gap between any two cannabis-policy positions in twenty years.
The most operationally urgent piece of the order is the registration window. State medical marijuana licensees that submit a DEA Schedule III registration application within 60 days of Federal Register publication — by Monday, June 22, 2026 — may continue operating under their existing state licenses during DEA review. The DEA has committed to processing those early applications within six months.
Three things matter about that window:
First, this isn't optional for medical operators who want the protections of Schedule III. The Schedule III protections, including 280E relief, are tied to operating as a DEA-registered Schedule III handler. A medical license without DEA registration doesn't capture the federal benefit; it just keeps the state-side authorization you already had.
Second, the application is substantive, not perfunctory. DEA registration for Schedule III handlers requires controlled-substance security protocols that most state-licensed medical operators are not currently running. Diversion prevention, recordkeeping under 21 C.F.R. parts 1304 and 1305, biennial inventories, suspicious order monitoring — these aren't state-level compliance items, they're new federal obligations layered on top of the state framework.
Third, applications filed after June 22 don't get the safe harbor. They go to the back of the line and have to convince DEA that the applicant has been operating in compliance with both Schedule III and the Single Convention. That's a much harder posture to defend than a timely-filed application.
For a more granular walkthrough of what registration entails, see our Schedule III operational readiness checklist.
The DEA hearing scheduled to begin June 29, 2026 at the agency's Arlington facility is the resumption of broader rescheduling. Parties seeking to participate had to submit notice by May 28. The hearing is set to conclude no later than July 15.
The hearing's job is to build a record on whether marijuana — as a whole, including recreational — should move from Schedule I to Schedule III. It is the proceeding the May 2024 NPRM was meant to feed, restarted on a fresh procedural foundation. The administration's decision to immediately reschedule medical via the treaty pathway, then restart the broader hearing on a clean slate, is widely understood as a deliberate sequencing choice. The first move builds an evidentiary record about cannabis being internationally accepted as having medical use; that record then becomes harder for opposition witnesses to attack at the June hearing.
What the hearing can do, if it concludes with broader rescheduling: extend Schedule III treatment to recreational cannabis, which would carry 280E relief into adult-use markets. That is the single largest dollar-value question in the entire cannabis industry right now. Cannabis Regulators Association estimates put recreational operators' effective federal tax rates at 70 to 80 percent under 280E. Schedule III drops that to roughly 20 to 30 percent. Across the industry, the difference is measured in billions of dollars per year.
What the hearing can't do: legalize cannabis. Schedule III is a controlled substance classification. Even if the broader rescheduling proceeds and survives legal challenge, recreational use without a federal pathway remains federally illegal. The same is true today for medical: rescheduled, but illegal absent state license and DEA registration. Anyone telling clients that rescheduling means legalization is wrong, and the practical consequence of that confusion will show up in the first round of post-rescheduling litigation.
Smart Approaches to Marijuana and aligned anti-rescheduling groups have already announced plans to challenge the April 23 order. The legal theories on the table include:
The treaty-compliance pathway under § 811(d) requires the Attorney General to demonstrate that rescheduling is necessary to comply with international treaty obligations. Opponents argue that the Single Convention on Narcotic Drugs does not, on its face, require Schedule III treatment of state-licensed medical marijuana — and that the administration is using a procedural shortcut to bypass the broader rulemaking record.
The split treatment of medical and recreational under the same federal classification scheme has its own statutory wrinkles. The Controlled Substances Act schedules substances, not commercial activities. The April 22 order schedules certain marijuana products by reference to the regulatory status of the seller, which is a structurally novel approach. Whether that survives APA review is one of the live questions.
Operators making investment decisions on the back of the rescheduling — especially decisions that depend on 280E relief flowing through — should be modeling at least one scenario where the order is enjoined or vacated within 12 to 24 months. That doesn't mean don't act. It means stress-test the cash flow under both outcomes.
The single most under-discussed consequence of the April 22 order is the compliance load it creates for medical-only operators that elect into DEA registration. Schedule III registration brings:
That's a real workload, and most operators have not staffed for it. The compliance ripple effects of rescheduling extend well beyond the headline tax change — we mapped the broader picture in Schedule III, Then What? Rescheduling's Hidden Compliance Ripple Effects, and the practical readiness items in Schedule III, 280E Relief, and the Limits of Rescheduling.
Federal rescheduling does not preempt state cannabis frameworks. A state medical-only license is the qualifier for Schedule III treatment, but the state itself is free to amend, restrict, or expand its medical program in ways that affect whether a license remains "qualifying" under the federal order.
Two patterns are likely to emerge over the next 12 months:
States with separate medical and adult-use licensure are going to see operators reorganize so that medical activity sits in a distinct legal entity, with distinct inventory and accounting, to capture clean Schedule III treatment. Expect ownership restructurings, intercompany agreements, and revised real-estate arrangements at scale. Auditors are going to need to develop a defensible position on transfer pricing between the medical-eligible entity and the still-Schedule-I adult-use entity.
States that fold medical into adult-use over the next year — a trend we've already seen in markets like Maryland and Missouri — are going to face pressure from licensees not to merge the programs, because doing so could disqualify medical operators from Schedule III treatment. State regulators are going to have to think about federal-tax consequences of program-design decisions in a way they never have before.
For the broader picture of what's shifting in 2025 and 2026 at the state level, see our Major Cannabis Regulation Changes overview.
The capital-markets reaction has been measured, and that's appropriate. Schedule III for medical-only doesn't fix the U.S. capital-markets problem for plant-touching cannabis companies. The major U.S. exchanges — NYSE, Nasdaq — have continued to decline plant-touching listings on the basis that the underlying activity remains federally illegal under any honest reading of the CSA. Schedule III medical activity is now arguably "federal-legal" if you stretch the term, but the exchanges have shown no interest in stretching it.
Where the order does change the picture: lending. Banks and specialty lenders that previously declined cannabis credit on the strength of Schedule I status now have a defensible answer for medical-only credit. The pricing should compress. The collateral picture is also better, because Schedule III inventory is theoretically capable of clean federal treatment in the way that Schedule I inventory is not. We've covered the practical knock-on effects for payments and lending in Schedule III and Cannabis Banking and Hemp & Cannabis Payments 2026.
For M&A, the bid-ask spread on medical-heavy operators just narrowed. Recreational-heavy operators are pricing in optionality on the June hearing. The clearest near-term opportunity is in vertically integrated operators that can spin off the medical business cleanly, capture the Schedule III treatment, and hold the adult-use side as a separate legal entity. Expect that deal structure repeatedly through Q2 and Q3.
There are a handful of questions that the April 22 order didn't resolve, and that operators and advisors should be tracking weekly:
How does DEA treat a medical-only license that authorizes wholesale distribution to an adult-use entity? The cleanest reading of the order is that the wholesale activity drops out of Schedule III at the moment of transfer. The DEA hasn't said so explicitly.
What happens to product manufactured before April 22 that was Schedule I in the ground but is now in inventory at a medical-only licensee? Inventory transition rules are pending.
When does Treasury issue 280E transition guidance? The Treasury press release of April 23 promised guidance and signaled a transition rule that applies for the full taxable year that includes the effective date. We covered the tax mechanics in detail in our companion piece on the operator-and-CPA tax playbook, and the 280E Survival Stack for the year-end-close finance controls.
Will the DEA process the early-window registration applications uniformly, or selectively? The six-month commitment is firm on paper. Implementation across the agency's eight regional divisions has been inconsistent on past expedited dockets.
Does the June 29 hearing produce a broader rescheduling? The procedural footing is better than it was in 2024. The witness universe is the same universe that fought the May 2024 NPRM to a stalemate. The realistic odds are between 40 and 60 percent depending on which side's submission you read this week, and any number tighter than that is overconfidence.
If you're a state-licensed medical operator: identify whether you're filing for Schedule III registration, and start the application now. The June 22 deadline is real and the application is non-trivial.
If you're an attorney or compliance officer for a multi-state operator: begin the entity-segregation analysis if you haven't. The cleanest 280E posture for FY2026 is going to require a defensible separation of medical and adult-use activity, and that takes more than ninety days to do well.
If you're a CFO or tax director: model two FY2026 scenarios — one where Treasury's transition guidance treats the whole year as Schedule III for medical, one where it doesn't — and a third FY2027 scenario contingent on the June hearing's outcome. Build the cash-flow effects out, because banking-covenant compliance and tax-distribution planning will both be affected.
If you're an investor or lender: this is a moment to revisit covenant baskets, MAC clauses, and event-of-default triggers tied to "scheduling change." A meaningful number of credit agreements drafted between 2022 and 2024 contain language that maps awkwardly onto the partial rescheduling. Better to discover the mismatch now.
The April 22 order is a real change. It is not the change that the market priced in over the back half of 2025, and the operators who are going to capture the benefit are the ones who treat it as a partial rescheduling with a 60-day federal-registration sprint, not as a quiet legalization of the medical side.
The broader question — recreational, full Schedule III, the end of 280E for adult-use — is not resolved. The June 29 hearing matters, the litigation matters, and the next round of agency guidance from Treasury, FDA, and DEA matters more than any of them. Track the dockets, model the outcomes, file the applications.
For ongoing analysis on the implementation track and what the June hearing surfaces, the team at cannabisregulations.ai is publishing weekly updates on rescheduling, 280E, banking, and Schedule III readiness.
